<qa>  What is the dose adjustment recommended for all participants?This study will enroll HIV-1-infected and HIV-1-uninfected pregnant women with latent TB and their infants into two cohorts based on gestation. Cohort 1 participants will be enrolled in their second trimester greater than or equal to 14 to less than 28 weeks, and Cohort 2 participants will be enrolled in their third trimester greater than or equal to 28 to less than or equal to 34 weeks. All participants will receive 12 directly observed once-weekly doses of RPT, INH, and pyridoxine vitamin B6 during their study visits at weeks 1-12. Study researchers will perform an interim analysis during the study, and a dose adjustment may be recommended based on this analysis. 